September 30th 2024
The event will focus on innovating with cutting-edge technology, featuring the likes of pharmaceutical technology companies revolutionizing the industry.
FDA approves REMS for ER, long-acting opioids
July 17th 2012FDA has approved a new risk evaluation and mitigation strategy for extended-release and long-acting opioids that requires that healthcare professionals are educated on how to safely prescribe the drugs and that patients understand how to safely use the drugs.
FDA: Single IV dose of ondansetron may cause potentially fatal heart rhythms
July 12th 2012FDA is alerting healthcare professionals to the possibility that a 32-mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) could lead to QT interval prolongation, putting patients at risk for a potentially fatal heart rhythm known as Torsades de Pointes.
FDA: No major safety concerns with compounded hydroxyprogesterone caproate
July 10th 2012FDA recently released the results of an analysis of a limited number of samples of hydroxyprogesterone caproate active pharmaceutical ingredients and compounded hydroxyprogesterone caproate, finding no major safety concerns.